Impact of Azathioprine use in chronic hypersensitivity pneumonitis patients
ConclusionsThis is the first study identifying an improvement in lung function (FVC) of CHP patients on AZA treatment for 2 years. Prospective studies are needed to confirm these results and to more adequately select CHP patients who may benefit from AZA.
Source: Pulmonary Pharmacology and Therapeutics - Category: Respiratory Medicine Source Type: research
More News: Carbon Monoxide Poisoning | Corticosteroid Therapy | Drugs & Pharmacology | Respiratory Medicine | Statistics | Study